Business
Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026
PITTSBURGH, April 21, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its first quarter 2026 financial results on Monday, May 4, 2026, prior to the open of U.S. markets. The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, May 4, 2026, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: https://www.webcaster5.com/
About this update from Krystal Biotech, Inc.
[{"type":"image","alt":"Krystal Biotech, Inc.","displaySize":"","headline":null,"caption":"Krystal Biotech, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/65807d69171535c646e8328b9e91b8eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Zsnb4.XQl64tDl7p9EaeHg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4/https://media.zenfs.com/en/globenewswire.com/65807d69171535c646e8328b9e91b8eb","width":300,"height":56}},"lazy":false},{"type":"text","content":"PITTSBURGH, April 21, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its first quarter 2026 financial results on Monday, May 4, 2026, prior to the open of U.S. markets.","length":235,"tagName":"p"},{"type":"text","content":"The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, May 4, 2026, to discuss the financial results and provide a business update.","length":181,"tagName":"p"},{"type":"text","content":"Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/53916.","length":116,"tagName":"p"},{"type":"text","content":"For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company’s website at www.krystalbio.com.","length":173,"tagName":"p"},{"type":"text","content":"About Krystal Biotech, Inc.Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).","length":793,"tagName":"p"},{"type":"text","content":"CONTACTInvestors and Media: &nb...